English | 简体中文 | 繁體中文 | 한국어 | 日本語
  Press Releases
Tuesday, December 26, 2023
大分大学とエーザイ、リストバンド型生体センサを用いた脳内アミロイドベータ蓄積予測モデルの開発
Tuesday, December 19, 2023
Eisai Submits Marketing Authorization Application in Japan for Anticancer Agent Tasurgratinib for Biliary Tract Cancer with Fgfr2 Gene Fusion
Thursday, December 14, 2023
Eisai and Mizuho Sign Sustainability-Linked Loan Agreement
"LEQEMBI Intravenous Infusion" (Lecanemab) for the Treatment of Alzheimer's Disease to be Launched in Japan on December 20
Monday, December 11, 2023
Eisai and Merck & Co., Inc., Rahway, NJ, USA Provide Update on Phase 3 LEAP-001 Trial Evaluating LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) as First-Line Treatment for Patients with Advanced or Recurrent Endometrial Carcinoma
Thursday, November 30, 2023
Eisai's Sales Subsidiary Collaborates with Ministry of Public Health (MOPH) in Thailand
Wednesday, November 22, 2023
Eisai to Present Latest Data on Perampanel at The 77th American Epilepsy Society (AES) Annual Meeting
Monday, November 20, 2023
LEQEMBI Wins Best New Drug And Clinical Advance of The Year at The Scrip Awards 2023
Wednesday, October 25, 2023
LEQEMBI (lecanemab-Irmb) Named One of Time's Best Inventions of 2023
Monday, October 16, 2023
Eisai to Present New Data from LEQEMBI (Lecanemab-Irmb) Phase 3 Clarity Ad Study and Other Alzheimer's Disease Pipeline Research at The Clinical Trials on Alzheimer's Disease (CTAD) Conference

Copyright © 2024 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Cookies Policy | Privacy Policy | Disclaimer | Terms of Use | RSS
US: +1 214 890 4418 | China: +86 181 2376 3721 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575